www.fdanews.com/articles/75809-dyax-files-shelf-for-up-to-9-million-shares
DYAX FILES SHELF FOR UP TO 9 MILLION SHARES
August 26, 2005
Biopharmaceutical firm Dyax Corp. (DYAX.O: Quote, Profile, Research) said on Friday that it may periodically sell up to 9 million common shares. The company said in a shelf registration statement filed with the U.S. Securities and Exchange Commission that it plans to use the proceeds for general corporate purposes, which may include working capital, capital spending, search and development, clinical trials, acquisitions and debt repayment.